{"denoms":[{"counts":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"127"}],"units":"Participants"}],"groups":[{"description":"Brentuximab vedotin (BV) monotherapy in adults age 60 and above with classical Hodgkin Lymphoma (cHL). BV (1.8 mg/kg) was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle.","id":"BG000","title":"Part A"},{"description":"BV in combination with dacarbazine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Dacarbazine (375 mg/m\\^2) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"BG001","title":"Part B"},{"description":"BV in combination with bendamustine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Bendamustine (70 mg/m\\^2) was administered as an IV infusion on Day 1 and Day 2 of each 21-day cycle.","id":"BG002","title":"Part C"},{"description":"BV in combination with nivolumab as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Nivolumab (3 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"BG003","title":"Part D"},{"description":"BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"BG004","title":"Part E"},{"description":"BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"BG005","title":"Part F"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"12"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"29"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"115"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"53"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"74"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"11"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"28"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"116"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"26"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"117"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"28"}]}],"title":"Grade 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"63"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"28"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"7"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}],"title":"Grade 5"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]}],"title":"Missing"}],"description":"0=Normal activity, 1=Symptoms but ambulatory, 2=In bed \\<50% of the time, 3=In bed \\>50% of the time, 4=100% bedridden, 5=Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"The Full Analysis Set includes all participants who received any amount of brentuximab vedotin."}